Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates IGF and interacts with the TGF-B pathway. IGFBP3 promoter methylation may occur in colorectal cancer with or without the CpG island methylator phenotype (CIMP), which is associated with microsatellite instability (MSI) and TGFBR2 mutation. We examined the relationship between IGFBP3 methylation, p53 expression, CIMP and MSI in 902 population-based colorectal cancers. Utilizing real-time PCR (MethyLight), we quantified promoter methylation in IGFBP3 and eight other CIMPhigh-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2 , MLH1, NEUROG1, RUNX3, and SOCS1). IGFBP3 methylation was far more frequent in non -MSI-high CIMP-high tumors (85% = 35/41) than in MSI-high CIMPhigh (49% = 44/90, P < .0001), MSI-high non -CIMP-high (17% = 6/36, P < .0001), and non -MSI-high non -CIMPhigh tumors (22% = 152/680, P < .0001). Among CIMPhigh tumors, the inverse relationship between MSI and IGFBP3 methylation persisted in p53-negative tumors (P < .0001), but not in p53-positive tumors. IGFBP3 methylation was associated inversely with TGFBR2 mutation in MSI-high non -CIMP-high tumors (P = .02). In conclusion, IGFBP3 methylation is inversely associated with MSI in CIMP-high colorectal cancers, and this relationship is limited to p53-negative tumors. Our data suggest complex relationship between global genomic/epigenomic phenomena (such as MSI/ CIMP), single molecular events (e.g., IGFBP3 methylation, TP53 mutation, and TGFBR2 mutation), and the related pathways. Neoplasia (2007) 9, 1091 -1098
Introduction
Insulin-like growth factor binding protein 3 (IGFBP3) is the main carrier of insulin-like growth factors (IGFs) in the circulation, where this complex regulates biologic function of IGFs [1] .
IGFBP3 has been shown to regulate both cell growth and death, independently of its interaction with IGFs [2, 3] . IGFBP3 promoter methylation and gene silencing are observed in human cancers including colorectal cancer [4, 5] , and have been associated with poor clinical outcome in lung and ovarian cancers [6, 7] . IGFBP3 is induced by wild-type p53 [8] , and promoter methylation at the p53 regulatory element causes gene silencing resistant to p53 [9] . IGFBP3 enhances the p53-dependent apoptotic response of colorectal adenoma cells to DNA damage [10] . IGFBP3 is known to interact with the transforming growth factor -beta (TGF-b) pathway [11 -13] .
Transcriptional inactivation by cytosine methylation at promoter CpG islands of tumor suppressor genes is an important mechanism in human carcinogenesis [14] . A number of tumor suppressor genes can be silenced by promoter methylation in colorectal cancers [14] . A subset of colorectal cancers exhibit widespread promoter CpG island methylation, which is referred to as the CpG island methylator phenotype (CIMP) [15] . CIMP-high colorectal tumors have a distinct clinical, pathologic, and molecular profile, such as associations with proximal tumor location, female, poor differentiation, BRAF mutation, wild-type tumor protein p53 (TP53 ), and inactive WNT/ CTNNB1 (b-catenin) [16] [17] [18] [19] [20] [21] [22] [23] [24] , independent of microsatellite instability (MSI) status [19] [20] [21] [22] [23] . In addition, CIMP-high in microsatellite instability -high (MSI-H) colorectal cancer is correlated with the transforming growth factor b receptor type 2 gene (TGFBR2) mononucleotide mutation [25] . Molecular classification of colorectal cancer based on CIMP and MSI is increasingly important [26, 27] because MSI and CIMP represent global genomic and epigenomic phenomena, respectively, in tumor cells, and largely determine pathologic and molecular features of colorectal cancer [27] .
In this study, using quantitative DNA methylation analysis (MethyLight) and a large number of population-based colorectal cancers, we have examined the relationship between IGFBP3 promoter methylation and various molecular features in colorectal cancer, including MSI, CIMP, p53, and mutations in TGFBR2 and BCL2-associated X protein (BAX). Discovering molecular correlates is important in cancer research, because it may: 1) provide clues to pathogenesis; 2) propose or support the existence of a new molecular subtype; 3) alert investigators to be aware of potential confounding in association studies; and 4) suggest surrogate markers in clinical or research settings [27] .
Materials and Methods

Study Group
We used the databases of two large prospective cohort studies: the Nurses' Health Study (N = 121,700 women followed since 1976) [28] and the Health Professionals Follow-Up Study (N = 51,500 men followed since 1986) [29] . Informed consent was obtained from all participants before inclusion in the cohorts. A subset of the cohort participants developed colorectal cancers during prospective follow-up. Thus, these colorectal cancers represented populationbased, relatively unbiased samples (compared to retrospective or single-hospital-based samples). Previous studies on the cohorts have described baseline characteristics of cohort participants and incident colorectal cancer cases, and confirmed that our colorectal cancer cases were well-represented as a population-based sample [28, 29] . We collected paraffinembedded tissue blocks from hospitals where cohort participants with colorectal cancers had undergone resections of primary tumors. We excluded cases if adequate paraffinembedded tumor tissue was not available at the time of the study. As a result, a total of 902 colorectal cancer cases (405 from men's cohort and 497 from women's cohort) were included. Among our cohort studies, there was no significant difference in demographic features between cases with tissue available and those without available tissue [30] . Many of the cases have been previously characterized for status of CIMP, MSI, KRAS, and BRAF [23] . However, no tumor has been examined for IGFBP3 methylation in our previous studies. Tissue collection and analyses were approved by the DanaFarber/Harvard Cancer Center and Brigham and Women's Hospital Institutional Review Boards.
Histopathologic Evaluations
Hematoxylin and eosin (H&E) -stained tissue sections were examined under a light microscope by one of the investigators (S.O.) blinded from clinical and other laboratory data as previously described [22] . The following eight features were evaluated: 1) the presence and extent of extracellular mucin were categorized as negative (no mucin), < 50%, or z50% of the tumor volume; 2) the presence and extent of signet ring cells were categorized as negative (no signet ring cells), < 50%, or z 50% of the tumor volume; 3) degree of tumor differentiation was categorized as well/ moderate (z 50% gland formation) versus poor (< 50% gland formation); 4) to 6) the degree of Crohn's-like lymphoid reaction (defined as transmural lymphoid aggregates), the degree of a peritumoral lymphocytic reaction (defined as a discrete lymphoid infiltrate surrounding tumor cell nests), and the degree of tumor-infiltrating lymphocytes were graded as absent/mild versus moderate/severe; 7) the extent of extraglandular tumor necrosis was graded as < 20% vs z 20%; and 8) the type of tumor border was categorized as circumscribed versus infiltrative.
Genomic DNA Extraction and Whole Genome Amplification
Genomic DNA was extracted from dissected tumor tissue sections using QIAmp DNA Mini Kit (Qiagen, Valencia, CA) as previously described [31] . Normal DNA was obtained from colonic tissue at resection margins. Whole genome amplification of genomic DNA was performed by polymerase chain reaction (PCR) using random 15-mer primers for subsequent MSI and loss of heterozygosity (LOH) analyses and KRAS and BRAF sequencing [31] . Previous studies by us and others showed that whole genome amplification did not significantly affect subsequent genetic analysis [31, 32] .
Analyses for MSI and 18q LOH
Methods to analyze for MSI and TGFBR2 mutation have been previously described [25, 33] . In addition to the recommended MSI panel consisting of D2S123, D5S346, D17S250, BAT25, and BAT26 [34] , we also used BAT40, D18S55, D18S56, D18S67, and D18S487 (i.e., 10-marker panel) [33] . A high degree of MSI (MSI-H) was defined as the presence of instability in z 30% of the markers. A low degree of MSI (MSI-L) was defined as the presence of instability in < 30% of the markers, and microsatellite stable (MSS) tumors were defined as tumors without an unstable marker. PCR primers for BAX mononucleotide repeat were: BAX-F, FAM-5V -atc cag gat cga gca ggg cg-3V; BAX-R, 5V -act cgc tca gct tct tgg tg-3V. PCR cycles consisted of initial denaturing at 94jC for 2 minutes, followed by 45 cycles of 94jC for 30 seconds, 55jC for 30 seconds, and 72jC for 30 seconds; and a final extension at 72jC for 2 minutes. PCR products were analyzed by ABI 3730 (Applied Biosystems, Foster City, CA). The presence of a peak at an altered size in tumor DNA compared to normal DNA was interpreted as positivity for BAX mutation.
For 18q LOH analysis using microsatellite markers D18S55, D18S56, D18S67, and D18S487, we duplicated PCR reaction and electrophoresis in each sample to exclude allele dropouts of one of two alleles [33] . LOH at each locus was defined as 40% or greater reduction of one of two allele peaks in tumor DNA relative to normal DNA. Overall 18q LOH positivity was defined as the presence of one or more markers with LOH, and overall 18q LOH negativity as the presence of two or more informative markers and the absence of LOH in all informative markers.
Sequencing of KRAS and BRAF
Methods of PCR and sequencing targeted for KRAS codons 12 and 13, and BRAF codon 600 have been previously described [31, 35] . Pyrosequecing was performed using the PSQ96 HS System (Biotage AB and Biosystems, Uppsala, Sweden) according to the manufacturer's instructions.
Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis
Sodium bisulfite treatment on genomic DNA was performed as previously described [36] . Real-time PCR to measure DNA methylation (MethyLight) was performed as previously described [37] . Using ABI 7300 (Applied Biosystems), we examined IGFBP3 promoter and eight other CIMPspecific promoters [calcium channel, voltage-dependent, T type alpha-1G subunit (CACNA1G), cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16), cellular retinoic acid binding protein 1 (CRABP1), insulin-like growth factor 2 (IGF2), MLH1, neurogenin 1 (NEUROG1), runt-related transcription factor 3 (RUNX3), and suppressor of cytokine signaling 1 (SOCS1)] [20, 24] . We have shown that these eight markers are sensitive and specific markers for CIMP-high [23] . The collagen 2A1 gene (COL2A1) was used to normalize for the amount of input bisulfite-converted DNA [36] . The primers and probe for IGFBP3 were (bisulfite-converted nucleotides are in italics): IGFBP3-F, 5V -GT T T CG GGC GTG AGT ACG A -3V (GenBank No. M35878, nucleotides 1692 -1710); IGFBP3-R, 5V -GAA TCG ACG CAA ACA CGA CTA C-3V (GenBank No. M35878, nucleotides 1789 -1810); and IGFBP3-probe, 6FAM -5V -T CG GT T GT T TAG GGC GAA GTA CGG G -3V -BHQ-1 (GenBank No. M35878, nucleotides 1760 -1784) [38] . Other primers and probes were previously described [24] . The PCR condition was as follows: initial denaturation at 95jC for 10 minutes followed by 45 cycles at 95jC for 15 seconds and 60jC for 1 minute. A standard curve was made for each PCR plate by duplicated PCR amplifications for COL2A1 on bisulfite-converted human genomic DNA at four different concentrations (in a 5-fold dilution series). The percentage of methylated reference (PMR; i.e., degree of methylation) at a specific locus was calculated by dividing the GENE/COL2A1 ratio of template amounts in a sample by the GENE/COL2A1 ratio of template amounts in SssItreated human genomic DNA (presumably fully methylated) and multiplying this value by 100 [37] . A PMR cutoff value of 4 (except for 6 in CRABP1 and IGF2) was based on previously validated data [36] . Precision and performance characteristics of bisulfite conversion and subsequent MethyLight assays have been previously evaluated and the assays have been validated [36] . CIMP-high was defined as the presence of z 6 of 8 methylated promoters, CIMP-low as 1 to 5 of 8 methylated promoters, and CIMP-0 as the absence (0 of 8) of methylated promoters, according to the previously established criteria [23] .
Tissue Microarrays (TMAs) and Immunohistochemistry for p53 and p21 (CDKN1A)
Tissue microarrays were constructed as previously described [39] . TMAs were constructed using the Automated Arrayer (Beecher Instruments, Sun Prairie, WI). Briefly, two 0.6-mm tissue cores each from a tumor and normal colonic mucosa were placed in each TMA block. Each TMA block will have a total of approximately 400 cores (100 cases). We examined two to four tumor tissue cores for each marker. A previous validation study have shown that examining two TMA cores can yield comparable results to examining whole tissue sections in more than 95% of cases [40] . We examined whole tissue sections for p21 in all cases, and for p53 in cases for which no tissue block was available for TMAs or results were equivocal in TMAs. Immunohistochemistry for p53 and p21 was performed as previously described [41, 42] . p53 positivity was defined as 50% or more of tumor cells with unequivocal strong nuclear staining, as this high threshold has been shown to improve specificity [43] . p21 loss was defined as less than 5% of tumor cells with nuclear staining. Appropriate positive and negative controls were included in each run of immunohistochemistry. All immunohistochemically stained slides were interpreted by one of the investigators (S.O.) blinded from any other clinical and laboratory data.
Statistical Analysis
In the statistical analysis, chi-square test (or Fisher's exact test when the number in any category was less than 10) was performed for categorical data, and kappa coefficients were calculated to determine the degree of agreement between two observers, using SAS program (Version 9.1, SAS Institute, Cary, NC). All P values were two-sided and statistical significance was set at P V .05.
Results
IGFBP3 Promoter Methylation Is Correlated with CIMP-High
Using MethyLight technology, we quantified DNA methylation in IGFBP3 and a panel of eight promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) [23, 24] . The latter eight promoters constitute a sensitive and specific marker panel for CIMP [23] . Among the 902 tumors, 258 (29%) were positive for IGFBP3 promoter methylation. There was no significant difference in the frequencies of IGFBP3 methylation between men (28%) and women (30%). Sensitivity and specificity of IGFBP3 methylation for the diagnosis of CIMP-high (z 6 of 8 methylated promoters, not including IGFBP3) were 60% and 77%, respectively (Table 1) . Thus, IGFBP3 methylation was not an excellent marker for CIMP-high, but was still positively correlated with CIMP-high (P < .0001). Because 5/8 methylated tumors showed borderline features between CIMP-high and CIMP-low [23] , we excluded those tumors from further analyses.
We also quantified IGFBP3 methylation in normal colon tissue in four IGFBP3-methylated tumor cases and 12 IGFBP3-unmethylated tumor cases. Only one normal sample among the four IGFBP3-methylated tumor cases showed IGFBP3 methylation, and all of the other normal samples showed unmethylated IGFBP3.
Inverse Relationship between IGFBP3 and MSI in CIMP-High Tumors
Because molecular classification based on MSI and CIMP status is increasingly important [26] , we stratified tumors into four categories according to MSI and CIMP status (Figure 1 ). Within CIMP-high tumors, the frequency of IGFBP3 methylation was significantly higher in MSI-L/MSS CIMP-high tumors (85%) than MSI-H CIMP-high tumors (49%, P < .0001), indicating an inverse relationship between IGFBP3 methylation and MSI in CIMP-high tumors. CIMP-low/0 tumors showed low frequencies (17 -22%) of IGFBP3 methylation regardless of MSI status.
IGFBP3 Methylation, CIMP, and Pathologic Features
Because IGFBP3 methylation is positively correlated with CIMP-high, we stratified tumors according to IGFBP3 and CIMP status in subsequent analyses (as in Tables 2 and 3) . Then, we could examine the effect of IGFBP3 methylation on various pathologic and molecular features independent of CIMP status. Table 2 summarizes the relations between IGFBP3 methylation and pathologic features in colorectal cancer. Proximal tumor location, poor differentiation, mucinous features, tumorinfiltrating lymphocytes, and Crohn's-like reaction were significantly associated with IGFBP3 methylation in all cases, but no significant correlations persisted after tumors were stratified by CIMP status. These findings indicate that those features are associated primarily with CIMP, but not directly with IGFBP3 methylation. Table 3 summarizes the relations between IGFBP3 methylation and other molecular features in colorectal cancer. Whereas MSI and IGFBP3 were not significantly correlated in all cases and CIMP-low/0 cases, MSI and IGFBP3 methylation were inversely correlated in CIMP-high tumors (P < .0001).
IGFBP3 Methylation, CIMP, and Other Molecular Features
Interestingly, IGFBP3 methylation and TGFBR2 mutation were inversely correlated (P = .02) in MSI-H CIMP-low/0 tumors, and IGFBP3 methylation and BAX mutation were positively correlated (P = .02) in MSI-H CIMP-high tumors (Table 3 ). These results may suggest possible interactions between the pathways related to these molecules (Figure 2) . BRAF mutation, 18q LOH, and p21 loss were correlated with IGFBP3 methylation in all cases, but the relations did not persist after tumors were stratified by CIMP status.
Relationship between IGFBP3 Methylation and MSI according to p53 or p21 Status
Because IGFBP3 is one of the downstream effectors of the p53 pathway (Figure 2) , we examined the interrelationship between MSI, IGFBP3, and p53 ( Figure 3 ). The inverse relationship between MSI and IGFBP3 methylation (in CIMPhigh tumors) persisted in p53-negative tumors (P < .0001), but not in p53-positive tumors. These results suggest that IGFBP3 methylation may be more important in TP53 wildtype tumors than in TP53-mutated tumors, which may have already downregulated IGFBP3.
We also examined the interrelationship between MSI, IGFBP3, and p21, one of the downstream effectors of p53 (Figure 4 ). The inverse relationship between MSI and IGFBP3 methylation persisted regardless of p21 status, suggesting that p21 and IGFBP3 functions were not directly linked.
Discussion
We conducted this study to examine IGFBP3 methylation in colorectal cancer, particularly in relation to MSI, CIMP, and p53. Molecular classification of colorectal cancer according to MSI and CIMP is increasingly important [26] , because MSI Specificity is defined as the number of IGFBP3-negative non -CIMP-high cases divided by the number of all non -CIMP-high cases. CIMP, CpG island methylator phenotype. and CIMP represent global genomic and epigenomic phenomena, respectively, in tumor cells, and largely determine clinical, pathologic, and molecular features of colorectal cancer. We have found that IGFBP3 methylation is inversely associated with MSI in CIMP-high tumors, but not in CIMPlow/0 tumors, and that this inverse relationship is limited to p53-negative tumors, but not p53-positive tumors. Our findings imply the complex interrelationship between genomic/ epigenomic phenomena (such as MSI and CIMP) and single molecular events, IGFBP3 methylation and p53 alteration, in colorectal cancer. Transcriptional inactivation of tumor suppressor genes by promoter CpG island methylation is an important mechanism in human carcinogenesis [14] . Epigenetic aberrations have been reported in various tumor-related genes [14,44 -47] . For quantitative DNA methylation analysis, we used MethyLight, which is robust and can reproducibly differentiate lowlevel methylation from high-level methylation [36, 48, 49] . Our resource of a large number of colorectal cancers, derived from two large prospective cohorts (relatively unbiased samples compared to retrospective or single-hospital-based samples), has enabled us to precisely estimate the frequency of colorectal cancers with a specific molecular feature (e.g., IGFBP3 methylation, MSI-H, and so forth). The large number of samples has also provided a sufficient power to accurately estimate the frequency of IGFBP3 methylation in rare tumor subtypes, such as MSI-L/MSS CIMP-high, CIMP-high p53-positive, and so forth.
IGFBP3 is one of the important downstream effectors of the p53 pathway [8, 10] , and is also known to interact with the TGF-b pathway [11 -13] (Figure 2) . Thus, we have examined the interrelationship between IGFBP3 methylation, p53 positivity, and MSI, and found that the inverse correlation between IGFBP3 methylation and MSI in CIMP-high tumors is limited to p53-negative tumors. Thus, IGFBP3 methylation may be important in TP53 wild-type tumors, whereas TP53-mutated tumors may have already downregulated IGFBP3 and IGFBP3 methylation may be less relevant. We have also found an inverse correlation between IGFBP3 methylation and TGFBR2 mutation in MSI-H CIMP-low/0 tumors, as well as a positive correlation between IGFBP3 methylation and BAX mutation in MSI-H CIMP-high tumors. These complex correlations suggest the intricate relationship between global genomic/epigenomic phenomena (such as MSI and CIMP), these single molecular events (such as IGFBP3 methylation, TP53 mutation, TGFBR2 mutation, and so forth), and the related pathways in colorectal cancer. In summary, IGFBP3 promoter methylation in colorectal cancer is inversely associated with MSI in CIMP-high colo- rectal cancer, and this inverse correlation is limited to p53-negative tumors. Further studies are necessary to elucidate the exact pathogenic role of IGFBP3 promoter methylation in colorectal cancer.
